U.S., March 25 -- ClinicalTrials.gov registry received information related to the study (NCT07491042) titled 'Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.' on March 12.
Brief Summary: This project aims to examine the effects of six-month treatment with selective SGLT2 inhibitor dapagliflozin in patients with end-stage kidney disease on chronic peritoneal dialysis.
Methods: A prospective, open label, single-arm interventional clinical trial, will conduct at Nizwa Hospital from March 1st, 2026, to August 31th , 2026, and includes thirty (30) end-stage kidney disease diabetic and non-diabetic patients on chronic peritoneal dialysis, will receive selective SGLT2i Dapagliflozin 10 mg once daily (OD). Clinical and laborat...